Zimberelimab clinical trials
Zimberelimab is named as an intervention in 28 current clinical trials in our USA, China, Spain, South Korea, Taiwan, Israel, Australia, UK, France, Italy, Canada, Turkey, Japan, Brazil, Germany, Mexico, Poland, Netherlands, Belgium, Austria, Portugal and Singapore registers. 13 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Gilead Sciences (9). The most-studied condition is Cervical Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Zimberelimab is approved
All regulators →- 2 EU orphan designations, most recently for treatment of gastric cancer (12 Sep 2025, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Zimberelimab works
All drug targets →- Programmed cell death protein 1 inhibitor InhibitorTarget: PDCD1 programmed cell death 1✓ In ChEMBL and the Guide to Pharmacology
- Cervical cancerPhase 3
- Classic Hodgkin lymphomaPhase 3
- Esophageal adenocarcinomaPhase 3
- Gastric adenocarcinomaPhase 3
- Gastroesophageal junction adenocarcinomaPhase 3
- Non-small cell lung carcinomaPhase 3
- Hodgkins lymphomaPhase 2
- Biliary tract cancerPhase 2
- Breast cancerPhase 2
- CancerPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297856, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12349, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Zimberelimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Zimberelimab
28 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Zimberelimab in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Zimberelimab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystectomy patients: phase II trial (preSAVE trial)
2024-516943-14-01 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Fondazione IRCCS Istituto Nazionale Dei Tumori | Italy |
Conditions studied with Zimberelimab
43 conditionsAll 43 conditions
| Condition (as registered) | Trials |
|---|---|
| Cervical Cancer | 4 |
| Solid Tumor | 2 |
| Non-small Cell Lung Cancer | 2 |
| Solid Tumors | 2 |
| Bladder Cancer | 2 |
| Lung Cancer | 1 |
| Advanced or Metastatic Non-Small-Cell Lung Cancer | 1 |
| Resectable Non-Small-Cell Lung Cancer | 1 |
| Metastatic Urothelial Cancer | 1 |
| Advanced Non-Small Cell Lung Cancer | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Clear Cell Renal Cell Carcinoma | 1 |
| Advanced Cancer | 1 |
| Advanced Malignancies | 1 |
| Advanced Solid Tumor | 1 |
| Advanced Solid Tumors | 1 |
| Neoplasm | 1 |
| Cancer, Malignant Tumors | 1 |
| Cervical Carcinoma | 1 |
| Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | 1 |
| Previously AG Chemotherapy Treated Pancreatic Cancer | 1 |
| Locally Advanced Cervical Cancer | 1 |
| Peritoneal Mesothelioma | 1 |
| Gestational Trophoblastic Tumor | 1 |
| Anaplastic Thyroid Carcinomas | 1 |
| Gastroenteropancreatic Neuroendocrine Tumor | 1 |
| Carcinoma, Neuroendocrine | 1 |
| Urothelial Bladder Carcinoma | 1 |
| Lung Diseases | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Resectable Lung Non-Small Cell Carcinoma | 1 |
| Bladder Urothelial Carcinoma | 1 |
| Bladder Neoplasm | 1 |
| Muscle-Invasive Bladder Carcinoma | 1 |
| Biliary Tract Cancer | 1 |
| Renal Cell Carcinoma | 1 |
| Kidney Cancer | 1 |
| Kidney Neoplasm | 1 |
| Renal Carcinoma | 1 |
| Advanced or Metastatic Solid Tumor | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Colorectal Cancer | 1 |
| Persistent, Recurrent, or Metastatic Cervical Cancer | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Gilead Sciences | 9 |
| Arcus Biosciences, Inc | 2 |
| Hospices Civils de Lyon | 2 |
| Taiho Pharmaceutical Co., Ltd | 2 |
| Guangzhou Gloria Biosciences Co., Ltd | 2 |
| Compugen Ltd | 1 |
| Sun Yat-sen University | 1 |
| Suzhou Municipal Hospital | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Shanghai Zhongshan Hospital | 1 |
| Tang-Du Hospital | 1 |
| RemeGen Co., Ltd | 1 |
| Fundación para el Progreso de la Oncología en Cantabria | 1 |
| Fundación GECP | 1 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 1 |
+ 1 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Zimberelimab trials
How many clinical trials are testing Zimberelimab?
28 current trials in our USA, China, Spain, South Korea, Taiwan, Israel, Australia, UK, France, Italy, Canada, Turkey, Japan, Brazil, Germany, Mexico, Poland, Netherlands, Belgium, Austria, Portugal and Singapore registers name Zimberelimab (also registered as AB122) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Zimberelimab trials recruiting patients?
Yes. 13 of the 28 trials are recruiting: 3 with sites in USA, 6 with sites in China, 2 with sites in Spain, 2 with sites in South Korea, 3 with sites in Israel, 2 with sites in Australia, 1 with sites in Canada and 2 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Zimberelimab clinical trials?
Gilead Sciences (9), Arcus Biosciences, Inc (2), Hospices Civils de Lyon (2) and Taiho Pharmaceutical Co., Ltd (2), among 16 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Zimberelimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Zimberelimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Zimberelimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.